HARP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 17.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Harpoon Therapeutics Insider Trading History Chart

Harpoon Therapeutics Share Price & Price History

^$23.01

+0.30 (1.20%)

As of 03/11/2024 01:00 AM ET

Harpoon Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/11/2024	Merck & Co., Inc.	Major Shareholder	Buy	21,397,205	$23.00	$492,135,715.00	1,000
3/23/2023	Ronald Hunt	Director	Buy	1,000	$10,000.00	$10,000,000.00	1,000

SEC Filings (Institutional Ownership Changes) for Harpoon Therapeutics (NASDAQ:HARP)

74.01% of Harpoon Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Harpoon Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/15/2024	Blackstone Inc.	815,000	$9.27M	0.0%	N/A	4.813%
2/14/2024	Commodore Capital LP	1,500,000	$17.06M	1.5%	N/A	8.859%
2/14/2024	New Leaf Venture Partners L.L.C.	1,859,168	$21.14M	17.0%	+489.0%	10.982%
2/9/2024	Franklin Resources Inc.	1,492,368	$16.97M	0.0%	+1,027.8%	8.815%
1/31/2024	abrdn plc	25,991	$0.30M	0.0%	N/A	0.154%
11/15/2023	Kennedy Capital Management LLC	52,987	$0.21M	0.0%	-90.0%	1.366%
11/14/2023	MPM Bioimpact LLC	319,670	$1.29M	0.3%	-90.0%	8.239%
11/13/2023	Acadian Asset Management LLC	7,670	$29K	0.0%	-90.0%	0.198%
8/8/2023	Sequoia Financial Advisors LLC	63,955	$45K	0.0%	-36.0%	0.199%
8/7/2023	Acadian Asset Management LLC	76,710	$53K	0.0%	-32.5%	0.239%
5/8/2023	Bailard Inc.	63,200	$47K	0.0%	N/A	0.168%
5/1/2023	CM Wealth Advisors LLC	50,354	$29K	0.0%	N/A	0.134%
4/25/2023	Sequoia Financial Advisors LLC	100,000	$74K	0.0%	+66.7%	0.267%
2/13/2023	Levin Capital Strategies L.P.	330,000	$0.24M	0.0%	N/A	0.997%
11/15/2022	Piper Sandler & CO.	580,815	$0.56M	0.5%	N/A	1.754%
11/14/2022	Ergoteles LLC	70,054	$68K	0.0%	-23.8%	0.212%
9/16/2022	Federated Hermes Inc.	132,791	$0.25M	0.0%	+45.0%	0.401%
8/12/2022	Franklin Resources Inc.	1,324,504	$2.53M	0.0%	-20.4%	4.003%
5/20/2022	International Biotechnology Trust PLC	151,445	$2.77M	0.6%	-29.6%	0.458%
5/13/2022	Tekla Capital Management LLC	259,910	$1.29M	0.0%	N/A	0.786%
5/12/2022	Connor Clark & Lunn Investment Management Ltd.	14,872	$74K	0.0%	-37.0%	0.045%
2/15/2022	Sender Co & Partners Inc.	14,252	$0.11M	0.1%	N/A	0.044%
2/15/2022	Kennedy Capital Management Inc.	129,766	$0.98M	0.0%	N/A	0.396%
2/14/2022	Point72 Asset Management L.P.	650,000	$4.91M	0.0%	N/A	1.985%
2/14/2022	GSA Capital Partners LLP	35,266	$0.27M	0.0%	+42.0%	0.108%
2/10/2022	Candriam Luxembourg S.C.A.	809,568	$6.11M	0.0%	+65.4%	2.472%
2/10/2022	Panagora Asset Management Inc.	85,059	$0.64M	0.0%	+113.0%	0.260%
2/10/2022	Connor Clark & Lunn Investment Management Ltd.	23,595	$0.18M	0.0%	+110.2%	0.072%
2/8/2022	Northern Trust Corp	191,251	$1.44M	0.0%	-3.4%	0.584%
1/28/2022	Allspring Global Investments Holdings LLC	4,621	$34K	0.0%	N/A	0.014%
11/16/2021	Schonfeld Strategic Advisors LLC	84,272	$0.67M	0.0%	+41.1%	0.258%
11/16/2021	Squarepoint Ops LLC	14,703	$0.12M	0.0%	N/A	0.045%
11/16/2021	Two Sigma Advisers LP	377,500	$2.98M	0.0%	N/A	1.155%
11/16/2021	Two Sigma Investments LP	406,470	$3.21M	0.0%	N/A	1.244%
11/16/2021	Laurion Capital Management LP	305,954	$2.42M	0.0%	-51.5%	0.936%
11/16/2021	Millennium Management LLC	602,752	$4.76M	0.0%	+994.7%	1.845%
11/15/2021	Cubist Systematic Strategies LLC	45,121	$0.36M	0.0%	+356.9%	0.138%
11/15/2021	Dynamic Technology Lab Private Ltd	23,602	$0.19M	0.0%	N/A	0.072%
11/15/2021	Franklin Resources Inc.	1,131,753	$8.94M	0.0%	-0.5%	3.464%
11/15/2021	GSA Capital Partners LLP	24,838	$0.20M	0.0%	+40.7%	0.076%
11/12/2021	Affinity Asset Advisors LLC	250,000	$1.98M	0.5%	+400.0%	0.765%
11/12/2021	Trexquant Investment LP	29,435	$0.23M	0.0%	N/A	0.090%
11/12/2021	Renaissance Technologies LLC	400,788	$3.17M	0.0%	N/A	1.227%
11/12/2021	Jump Financial LLC	31,200	$0.25M	0.0%	N/A	0.096%
11/12/2021	International Biotechnology Trust PLC	215,000	$1.70M	0.4%	N/A	0.658%
11/12/2021	Geode Capital Management LLC	380,213	$3M	0.0%	+8.0%	1.164%
11/12/2021	Connor Clark & Lunn Investment Management Ltd.	11,225	$89K	0.0%	N/A	0.034%
11/10/2021	Goldman Sachs Group Inc.	87,398	$0.69M	0.0%	-60.8%	0.268%
11/10/2021	Panagora Asset Management Inc.	39,929	$0.32M	0.0%	-49.5%	0.122%
11/10/2021	IndexIQ Advisors LLC	21,491	$0.17M	0.0%	+11.1%	0.066%
11/10/2021	Citigroup Inc.	3,817	$30K	0.0%	-96.4%	0.012%
11/9/2021	Barclays PLC	31,167	$0.25M	0.0%	-13.7%	0.095%
11/9/2021	BlackRock Inc.	1,733,182	$13.69M	0.0%	+1.2%	5.305%
11/8/2021	Summit Global Investments	10,800	$85K	0.0%	N/A	0.033%
11/8/2021	Los Angeles Capital Management LLC	55,476	$0.44M	0.0%	-8.1%	0.170%
11/4/2021	Deutsche Bank AG	11,329	$89K	0.0%	-37.4%	0.035%
11/2/2021	New York State Common Retirement Fund	5,809	$46K	0.0%	-66.5%	0.018%
10/19/2021	Assenagon Asset Management S.A.	94,242	$0.75M	0.0%	N/A	0.288%
9/3/2021	Parametric Portfolio Associates LLC	10,509	$0.15M	0.0%	N/A	0.032%

Data available starting January 2016

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Today's Range

Now: $23.01

$23.01

50 Day Range

MA: $22.89

$22.34

$23.01

52 Week Range

Now: $23.01

$3.11

$23.21

Volume

N/A

Average Volume

1,516,200 shs

Market Capitalization

$389.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

Who are the company insiders with the largest holdings of Harpoon Therapeutics?: Harpoon Therapeutics' top insider investors include:
Merck & Co, Inc (Major Shareholder)
Learn More about top insider investors at Harpoon Therapeutics.